EP Patent

EP3802627A4 — METHODS OF PREPARING SUGAMMADEX

Assigned to Merck Sharp and Dohme LLC · Expires 2022-03-09 · 4y expired

What this patent protects

Patent listed against tazemetostat-hydrobromide.

Drugs covered by this patent

tazemetostat-hydrobromide (TAZEMETOSTAT HYDROBROMIDE)

Patent Metadata

Patent number: EP3802627A4
Jurisdiction: EP
Classification: —
Expires: 2022-03-09
Drug substance claim: No
Drug product claim: No
Assignee: Merck Sharp and Dohme LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.